Xencor reported $-36.6M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Arrowhead Research USD -154.34M 13.08M Jun/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -65.25M 33.36M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Xencor USD -36.6M 41.26M Jun/2026